Ambroxol

Generic Name: Ambroxol

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈Br_₂N_₂O

CAS Number: 18683-91-5

Unique Ingredient Identifier: 200168S0CL

Background: Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the resp...

Indication: Ambroxol is indicated for secretolytic therapy in bronchoplmonary disease with abnormal mucus secretion and transport. It allows the mucus to be more easily cleared and ease a patient's breathing.

Associated Conditions: -

Associated Therapies: Airway secretion clearance therapy

Clinical Trials

High-Dose Ambroxol in GBA1-Related Parkinson

Phase 1

Recruiting

Conditions: Parkinson Disease
GBA Gene Mutation

Interventions: Drug: Ambroxol Hydrochloride

First Posted Date: 2024-01-05

Last Posted Date: 2024-02-08

Lead Sponsor: Agyany Pharma LTD

Target Recruit Count: 40

Registration Number: NCT06193421

Locations: 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel

A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS

Phase 2

Recruiting

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo
Drug: Ambroxol

First Posted Date: 2023-07-25

Last Posted Date: 2023-09-07

Lead Sponsor: The Florey Institute of Neuroscience and Mental Health

Target Recruit Count: 50

Registration Number: NCT05959850

Locations: 🇦🇺
Concord Repatriation General Hospital, Sydney, New South Wales, Australia
🇦🇺
Launceston General Hospital, Launceston, Tasmania, Australia
🇦🇺
Brain and Mind Centre, Sydney, New South Wales, Australia

and more 2 locations

GRoningen Early-PD Ambroxol Treatment

Phase 2

Recruiting

Conditions: Parkinson
Parkinson Disease

Interventions: Drug: Ambroxol Hydrochloride
Drug: Placebo

First Posted Date: 2023-04-26

Last Posted Date: 2023-05-10

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 80

Registration Number: NCT05830396

Locations: 🇳🇱
University Medical Center Groningen, Groningen, Netherlands

Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients

Phase 4

Completed

Conditions: Severe Pneumonia
Community-acquired Pneumonia
Hospital-acquired Pneumonia
Critical Illness

Interventions: Drug: Ambroxol Hydrochloride
Other: Standard Therapy

First Posted Date: 2022-12-23

Last Posted Date: 2023-12-27

Lead Sponsor: National University of Malaysia

Target Recruit Count: 32

Registration Number: NCT05663905

Locations: 🇲🇾
Hospital Canselor Tuanku Muhriz UKM (HCTM), Cheras, Kuala Lumpur, Malaysia

Ambroxol as a Disease-modifying Treatment in GBA-PD

Phase 2

Active, not recruiting

Conditions: Parkinson Disease
GBA Gene Mutation

Interventions: Drug: Ambroxol Hydrochloride
Drug: Placebo

First Posted Date: 2022-03-18

Last Posted Date: 2023-09-11

Lead Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Target Recruit Count: 65

Registration Number: NCT05287503

Locations: 🇮🇹
University of Campania "Luigi Vanvitelli", Naples, Italy
🇮🇹
IRCCS National Neurological Institute "C. Mondino" Foundation, Pavia, Italy
🇮🇹
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial

Phase 2

Recruiting

Conditions: Dementia With Lewy Bodies

Interventions: Drug: Placebo
Drug: Ambroxol

First Posted Date: 2020-10-19

Last Posted Date: 2023-12-21

Lead Sponsor: Helse Fonna

Target Recruit Count: 180

Registration Number: NCT04588285

Locations: 🇳🇴
Helse Fonna, Haugesund, Norway

Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia

Phase 1

Not yet recruiting

Conditions: Lewy Body Disease

Interventions: Other: Placebo
Drug: Ambroxol Hydrochloride

First Posted Date: 2020-05-28

Last Posted Date: 2023-12-13

Lead Sponsor: Lawson Health Research Institute

Target Recruit Count: 15

Registration Number: NCT04405596

Locations: 🇨🇦
Parkwood Institute, London, Ontario, Canada

Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy

Phase 2

Completed

Conditions: Gaucher Disease, Type 1

Interventions: Drug: Ambroxol

First Posted Date: 2019-05-15

Last Posted Date: 2023-02-14

Lead Sponsor: Shaare Zedek Medical Center

Target Recruit Count: 40

Registration Number: NCT03950050

Locations: 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel

A Study of the Effect of 20 mg Ambroxol Hydrochloride on Acute Cough.

Phase 2

Completed

Conditions: Cough

Interventions: Drug: Ambroxol Hydrochloride

First Posted Date: 2018-01-30

Last Posted Date: 2019-06-20

Lead Sponsor: Hull University Teaching Hospitals NHS Trust

Target Recruit Count: 14

Registration Number: NCT03415269

Locations: 🇬🇧
Castle Hill Hospital, Cottingham, East Yorkshire, United Kingdom

Ambroxol in Disease Modification in Parkinson Disease

Phase 2

Completed

Conditions: Parkinson Disease

Interventions: Drug: Ambroxol

First Posted Date: 2016-10-21

Last Posted Date: 2020-04-15

Lead Sponsor: University College, London

Target Recruit Count: 23

Registration Number: NCT02941822

Locations: 🇬🇧
Leonard Wolfson Experimental Neurology Centre Clinical Research Facility LWENC CRF, London, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy